This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ALS Reviewed By NeuroPerspective

CARDIFF, Calif., Feb. 11, 2013 /PRNewswire/ --  NI Research has released the February issue of NeuroPerspective. The issue features a comprehensive review of ALS, and the continuing but frustrating search for a genuinely useful treatment for the treatment of this devastating illness.

"Just as Alzheimer's slowly erases memory and personality, ALS gradually destroys muscle control, leaving patients almost invariably doomed to death from respiratory failure. The Phase III failure of Biogen-Idec/Knopp's dexpramipexole has provided yet another reminder of how difficult it has been to achieve any headway against ALS," said Harry Tracy, Ph.D., editor and publisher of NeuroPerspective.

The 21-page issue includes: 1) An overview of the pathophysiology of ALS; a reconsideration of SOD1 anomalies in recapitulating phenotype rather than genotype; and the growing interest in therapeutic approaches that address immunoreactive and inflammatory factors.

2) Programs covered in the review include those from Biogen-Idec and Isis Pharmaceuticals,  Neuraltus, Newron, NeuralStem, BrainStorm Cell Therapeutics, Cambria Pharmaceuticals, Regenesance, Amorfix, KineMed, and Cytokinetics, plus many others. The prominent role of ALS TDI in ALS research is noted, as is its intriguing program assessing the potential value of Novartis' Gilenya as an ALS therapeutic.

3) Other coverage and commentary in the February issue includes:

  • Genentech's licensing of the Afraxis PAK program
  • Executive Turbulence at AstraZeneca and EnVivo Pharmaceuticals
  • Teva and Tire Irons: The Risk of Going MAD

A brief summary review of Regenesance, developing therapeutics for disorders associated with complement activation.

The February issue of NeuroPerspective is being made available as a single-issue purchase: $150.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs